ClinicalTrials.gg

Program

XNW5004

A development code. Also written as “XNW5004 tablets”, “XNW5004 combined with CHOEP (incremental)” and “XNW5004 combined with CHOP (extended)”.

Its studies are mostly in Prostatic Neoplasms · Lymphoma, T-Cell, Peripheral · Lymphoma · Squamous Cell Carcinoma of Head and Neck · Lymphoma, Follicular, led by Evopoint Biosciences.

Furthest: phase 2, since Aug 17, 20237 company-led studies, 5 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Evopoint Biosciences75 open or runningphase 2since Aug 17, 2023Aug 17, 2023Jan 2027phase 2 · NCT06702605

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2023First study: phase 2 study in CarcinomaFirst studyNCT06022757 · 12 enrolled · China
  2. Aug 14, 2024Phase 2 study in LymphomaNCT06558513 · 120 enrolled · China
  3. Nov 11, 20242 phase 2 studiesNCT06702995, NCT06702605
  4. Mar 26, 2026Phase 2 study in Lymphoma, FollicularNCT07545603 · 65 planned · China
  5. Jul 8, 20262 phase 2 studiesNCT07730515, NCT07730580
  6. Oct 20, 2026Primary completion moved from 2026-05-13 to 2027-07-13Date moved laterphase 2 · +14 months · NCT06702995

Ahead

  1. Jan 2027Primary completion: phase 2 study in Lymphoma, T-Cell, PeripheralNCT06702605
  2. Jul 13, 2027Primary completion: phase 2 study in Metastatic Castrate-Resistant Prostate CancerNCT06702995
  3. Dec 31, 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT07545603
  4. Sep 30, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07730515

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07730580Advanced Prostate Cancer2Not yet recruitingDec 31, 2028242
NCT07730515Lymphoma, Non-Hodgkin · China2RecruitingSep 30, 2028176
NCT07545603Lymphoma, Follicular · China2RecruitingDec 31, 202765
NCT06702605Lymphoma, T-Cell, Peripheral2Not yet recruitingJan 202750
NCT06702995Metastatic Castrate-Resistant Prostate Cancer · China2RecruitingJul 13, 2027307
NCT06558513Lymphoma · China2CompletedAug 30, 2025120
NCT06022757Carcinoma · China2TerminatedJan 13, 202512

How it is read

Names in the registry

  • “XNW5004 tablets”, 3 entries
  • “XNW5004”, 2 entries
  • “XNW5004 combined with CHOEP (incremental)”, 1 entry
  • “XNW5004 combined with CHOP (extended)”, 1 entry
  • “XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone”, 1 entry

Codes read as this program: XNW5004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.